Title

Neural compression-induced neuralgias: clinical evaluation of the effect of nucleotides associated with vitamin B12 Links      Export Central Citation  

Author(s)

Goldberg H, Scussel Jr, AB, Cohen JC, Rzetelna H, Mezitis SGE, Nunes FP, Ozeri D, Daher JPL, Nunes CP, Oliveira L, Geller M

Source

Revista Brasileira de Medicina

Date of Publication

2009

Volume

66

Issue

11

Pages

380-5

Abstract

The use of a combination of uridine triphosphate (UTP), cytidine monophosphate (CMP), and hydroxocobalamin was evaluated in a double-blind, randomized study in the treatment of neuralgia due to degenerative orthopedic alterations with neural compression. Following informed consent, 80 patients were randomized to a 30 day treatment period. The subjects received a thrice-daily oral treatment regimen of either the combination treatment (Group A: total daily dose of 9mg UTP, 15mg CMP, 6 mg hydroxocobalamin) or vitamin B12 alone (Group B: total daily dose of 6 mg hydroxocobalamin). Efficacy measures evaluated global patient condition from the perspective of the subject and the investigating physician; pain - measured by a visual-analog scale; and functionality, using a patient-response questionnaire. The safety evaluation took into account physical evaluations and laboratory tests performed at each visit to the study center as well as the incidence and severity of adverse events. At the end of the 30-day treatment period, there were reductions in the pain scale scores in both groups, however there was a significantly larger reduction in the scores of the Group A patients. The Patient Global Evaluation scores improved in both groups but showed greater improvement in Group A, while the Physician Global Evaluation improved significantly only in Group A. A similar finding was observed in the scores of the Patient Functionality Questionnaire. Based on the findings of this clinical trial, we conclude that the combination of UTP, CMP, and vitamin B12 has a positive effect on pain and functionality improvement in the treatment of degenerative orthopedic alterations with neural compression, in the study population evaluated. Copyright Moreira Jr. Editora.

EMBASE keywords

Adult; Anxiety; Appetite; Article; Clinical Evaluation; Clinical Trial; Constipation; Si [Side Effect]; Controlled Clinical Trial; Controlled Study; Disease Severity; Double Blind Procedure; Drug Efficacy; Drug Safety; Epigastric Pain; Si [Side Effect]; Erythrocyte Sedimentation Rate; Female; Flatulence; Si [Side Effect]; Functional Assessment; Headache; Si [Side Effect]; Heartburn; Si [Side Effect]; Human; Incidence; Major Clinical Study; Male; Nausea; Si [Side Effect]; *Nerve Compression; *Neuralgia; Co [Complication]; *Neuralgia; Dt [Drug Therapy]; Pain Assessment; Physical Examination; Randomized Controlled Trial; Side Effect; Si [Side Effect]; Treatment Duration; Uric Acid Blood Level; Visual Analog Scale; *Cyanocobalamin; Ct [Clinical Trial]; *Cyanocobalamin; Dt [Drug Therapy]; Cytidine Phosphate; Ae [Adverse Drug Reaction]; Cytidine Phosphate; Ct [Clinical Trial]; Cytidine Phosphate; Cb [Drug Combination]; Cytidine Phosphate; Dt [Drug Therapy]; Cytidine Phosphate; Po [Oral Drug Administration]; Hydroxocobalamin; Ae [Adverse Drug Reaction]; Hydroxocobalamin; Ct [Clinical Trial]; Hydroxocobalamin; Cb [Drug Combination]; Hydroxocobalamin; Dt [Drug Therapy]; Hydroxocobalamin; Po [Oral Drug Administration]; Uridine Triphosphate; Ae [Adverse Drug Reaction]; Uridine Triphosphate; Ct [Clinical Trial]; Uridine Triphosphate; Cb [Drug Combination]; Uridine Triphosphate; Dt [Drug Therapy]; Uridine Triphosphate; Po [Oral Drug Administration]

Accession Number

EMBASE 2010034471

Study Design

RCT PT: Journal: Article

ID

CN-00802920

itle

Treatment of acute, non-traumatic pain using a combination of diclofenac-cholestyramine, uridine triphosphate, cytidine monophosphate, and hydroxycobalamin. Links      Export Central Citation  

Author(s)

Mibielli MA, Nunes CP, Cohen JC, Scussel AB, Higashi R, Bendavit GG, Oliveira L, Geller M

Source

Proceedings of the Western Pharmacology Society

Date of Publication

2010

Volume

53

Pages

5-12

Abstract

This randomized, controlled, double-blind clinical study in parallel groups evaluated the safety and efficacy of an oral combination diclofenac-cholestyramine, nucleotides (uridine and cytidine) and vitamin B12 versus the oral combination of nucleotides and vitamin B12 in the treatment of acute, non-traumatic pain. Subjects received twice-daily, 10-day oral administration of diclofenac-cholestyramine + uridine + cytidine + vitamin B12 (Group DN, n=40) or uridine + cytidine + vitamin B12 (Group NB, n=41). The primary study endpoint was the number of subjects with VAS reduction of >30mm after 10 days of treatment. Secondary endpoints included the number of patients with improvement >5 points in the Patient Functionality Questionnaire after 10 days of treatment, and the number of subjects presenting adverse events. Treatment with the combination of diclofenac-cholestyramine, nucleotides and Vitamin B12 resulted in a higher number of subjects with VAS score reductions >30mm after 10 days of treatment (87.5% subjects) than in the control group administered nucleotides and Vitamin B12 (51.23% of subjects), (p>0.0006). A significantly higher number of subjects in the DN group (80%) had a score reduction of >5 points in the Patient Functionality Questionnaire at after 10 days of treatment compared to Group NB (29.3%), (p<0.001). The number of subjects presenting AEs did not vary significantly between treatment groups (p=0.587). The combination of diclofenac-cholestyramine with uridine, cytidine and vitamin B12 was well-tolerated over a 10-day treatment period. The combination reduced pain and improved functionality among subjects presenting acute, non-traumatic pain in the lower back, hips, and neck.

Medical Subject Headings (MeSH)

Acute Disease; Anti-Inflammatory Agents, Non-Steroidal [*administration & dosage]; Cholestyramine Resin [*administration & dosage; adverse effects];Cytidine Monophosphate [*administration & dosage; adverse effects]; Diclofenac [*administration & dosage; adverse effects]; Double-Blind Method; Drug Therapy, Combination; Hydroxocobalamin [*administration & dosage; adverse effects]; Pain [*drug therapy]; Uridine Triphosphate [*administration & dosage; adverse effects]

MeSH check words

Adult; Female; Humans; Male; Middle Aged

Accession Number

PUBMED 22128442

Language

eng

Publication Type

Journal Article; Randomized Controlled Trial

ID

CN-00804698

Title

Effects of uridine in the treatment of diabetic neuropathy: an electrophysiological study. Links    Export Central Citation  

Author(s)

Gallai V, Mazzotta G, Montesi S, Sarchielli P, Del Gatto F

Source

Acta neurologica Scandinavica

Date of Publication

1992 Jul

Volume

86

Issue

1

Pages

3-7

Abstract

The authors performed a controlled double-blind neurophysiological study (uridine vs placebo) in 40 diabetic patients with peripheral neuropathy. Twenty subjects were treated with uridine and 20 with placebo. The neurophysiological evaluation consisted of a study of the MCV of the median nerve, the common Peroneal, the posterior Tibial, the SCV of the radial nerve, the median and the sural as well as the amplitudes of the motor and sensory responses. The nerves examined were on the dominant side. The evaluations were performed at baseline and after 60, 120, 180 days of therapy with a follow up control after 90 days from the completion of therapy. No statistically significant modifications were observed in the placebo group. In the drug group, the neurophysiological parameters improved significantly from the 120th day post therapy compared with baseline and were maintained through to follow up. The authors discuss the results which demonstrated that treatment with uridine can bring about a neurophysiological improvement in peripheral nerves.

Medical Subject Headings (MeSH)

Diabetes Mellitus, Type 1 [*drug therapy; physiopathology]; Diabetes Mellitus, Type 2 [*drug therapy; physiopathology]; Diabetic Neuropathies [*drug therapy; physiopathology]; Double-Blind Method; Drug Administration Schedule; Neurologic Examination [*drug effects]; Peripheral Nerves [drug effects; physiopathology]; Reaction Time [drug effects; physiology]; Synaptic Transmission [*drug effects; physiology]; Uridine [*administration & dosage]

MeSH check words

Female; Humans; Male; Middle Aged

Correspondence Address

Department of Neurology, University of Perugia, Italy.

Accession Number

PUBMED 1325728

Cochrane Group Code

SR-ENDOC; SR-NEUROMUSC

Language

eng

Publication Type

Clinical Trial; Journal Article; Randomized Controlled Trial

ID

CN-00086819